title: [Long-term results of treatment for T-cell lymphoblastic lymphomas].
abstract: OBJECTIVE
  To define the efficiency of the GMALL 2002 program for the treatment of patients with T-cell lymphoblastic lymphomas (T-LBL).
  
  
  METHODS
  Twenty-five patients with a verified diagnosis of T-LBL were examined. Male/female ratio was 19:6; median age was 33 (range 16-67) years. There was a preponderance of patients with the generalized stages of the diseases: 2, 5, and 18 with Stages II, III, and IV, respectively. Mediastinal lesion was found in 20 (80%) of the 25 patients. Their treatment was performed according to the GMALL 2002 program and similar CHOP courses. Analysis was made in 2 groups that were not different in their clinical and morphological characteristics. Group 1 consisted of 17 of the 25 patients treated according to the GMALL programs; Group 2 comprised 8 patients who had similar CHOP and other chemotherapy regimens.
  
  
  RESULTS
  In Group 1, 15 (88%) patients achieved a complete clinical and hematological remission and 2 (12%) patients died in the first stages of the treatment. No relapses were noted. The median survival had not been achieved; 5-year overall survival was 88 +/- 8%. In Group 2, three patients were alive; 2 completed their treatment; 5 (63%) patients died from treatment failures. The median survival was 23 +/- 18%; 5-year overall survival was 45%.
  
  
  CONCLUSIONS
  The findings suggest that the GMALL 2002 programs are highly effective in treating patients with T-LBL at the first stage of treatment.
authors.forename: Iu E
authors.initials: IuE
authors.lastname: Vinogradova
authors.forename: N G
authors.initials: NG
authors.lastname: Chernova
authors.forename: I B
authors.initials: IB
authors.lastname: Kaplanskaia
authors.forename: B V
authors.initials: BV
authors.lastname: Zingerman
authors.forename: Ia K
authors.initials: IaK
authors.lastname: Mangasarova
authors.forename: B B
authors.initials: BB
authors.lastname: Krasilnikova
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009031:Moscow; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult